Study cohort
| Subjects | Age | Sex | Parasites/µl | HRP2 | Temperature | |
| median (IQR) | M/F | median (IQR) | median ng/ml (IQR) | median °C (IQR) | ||
| Pf | 42 | 23 (18–35) | 27/15 | 5,655 (533–18,250) | 107 (1.06–9.28)a | 36.2 (36.1–37.9) |
| Pv | 25 | 23 (19–31) | 9/16 | 3,207 (1,020–8,067) | n.d. | 36.6 (36.3–37.1) |
| U | 17 | 27 (20–24) | 14/3 | n.d. | n.d. | 36 (35.5–36.3) |
| Subjects | Age | Sex | Parasites/µl | HRP2 | Temperature | |
| 42 | 23 (18–35) | 27/15 | 5,655 (533–18,250) | 107 (1.06–9.28) | 36.2 (36.1–37.9) | |
| 25 | 23 (19–31) | 9/16 | 3,207 (1,020–8,067) | n.d. | 36.6 (36.3–37.1) | |
| U | 17 | 27 (20–24) | 14/3 | n.d. | n.d. | 36 (35.5–36.3) |
36 subjects. 10 of the 42 Pf patients were analyzed at days 7 and 28 after treatment. No peripheral parasitemia or HRP2 was detected on any Pf patient at days 7 or 28 after treatment. There were no significant differences between any of these groups. n.d., not detected. U, uninfected.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.